Safety and Efficacy of Bexagliflozin as Monotherapy in Patients With Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 210 participants.

Also called NCT02715258

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 210 participants (enrolled count) (from the registry)
Sponsor
  • Theracos Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02715258
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02715258. Randomized; quadruple masking; primary purpose treatment. Start 2016-03 (actual); primary completion 2017-04 (actual). Results posted on 2021-04-28.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Efficacy of Bexagliflozin as Monotherapy in Patients With Type 2 Diabetes
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Bexagliflozin
Intervention (Drug)
Placebo
Lead sponsor
Theracos (class: industry)

Record details

Record id
cardio:ct-nct02715258
Content hash
866b96f3570faf70a4464887e19ad9767499698976f8ae4c5ff5fea70e4ab508